Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia

被引:1908
作者
Kapur, S
机构
[1] Ctr Addict & Mental Hlth, Clarke Div, PET Ctr, Toronto, ON M5T 1R8, Canada
[2] Ctr Addict & Mental Hlth, Schizophrenia Program, Toronto, ON M5T 1R8, Canada
[3] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
关键词
D O I
10.1176/appi.ajp.160.1.13
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The clinical hallmark of schizophrenia is psychosis. The objective of this overview is to link the neurobiology (brain), the phenomenological experience (mind), and pharmacological aspects of psychosisin-schizophrenia into a unitary framework. Method: Current ideas regarding the neurobiology and phenomenology of psychosis and schizophrenia, the role of dopamine, and the mechanism of action of antipsychotic medication were integrated to develop this framework. Results: A central role of dopamine is to mediate the "salience" of environmental events and internal representations. It is proposed that a dysregulated, hyperdopaminergic state, at a "brain" level of description and analysis, leads to an aberrant assignment of salience to the elements of one's experience, at a "mind" level. Delusions are a cognitive effort by the patient to make sense of these aberrantly salient experiences, whereas hallucinations reflect a direct experience of the aberrant salience of internal representations. Antipsychotics "dampen the salience" of these abnormal experiences and by doing so permit the resolution of symptoms. The antipsychotics do not erase the symptoms but provide the platform for a process of psychological resolution. However, if antipsychotic treatment is stopped, the dysregulated neurochemistry returns, the dormant ideas and experiences become reinvested with aberrant salience, and a relapse occurs. Conclusions: The article provides a heuristic framework for linking the psychological and biological in psychosis. Predictions of this hypothesis, particularly regarding the possibility of synergy between psychological and pharmacological therapies, are presented. The author describes how the hypothesis is complementary to other ideas about psychosis and also discusses its limitations.
引用
收藏
页码:13 / 23
页数:11
相关论文
共 175 条
  • [1] Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P761
  • [2] Increased baseline occupancy of D2 receptors by dopamine in schizophrenia
    Abi-Dargham, A
    Rodenhiser, J
    Printz, D
    Zea-Ponce, Y
    Gil, R
    Kegeles, LS
    Weiss, R
    Cooper, TB
    Mann, JJ
    Van Heertum, RL
    Gorman, JM
    Laruelle, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) : 8104 - 8109
  • [3] SCH 23390 BLOCKS DRUG-CONDITIONED PLACE-PREFERENCE AND PLACE-AVERSION - ANHEDONIA (LACK OF REWARD) OR APATHY (LACK OF MOTIVATION) AFTER DOPAMINE-RECEPTOR BLOCKADE
    ACQUAS, E
    CARBONI, E
    LEONE, P
    DICHIARA, G
    [J]. PSYCHOPHARMACOLOGY, 1989, 99 (02) : 151 - 155
  • [4] Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients
    Anand, A
    Verhoeff, P
    Seneca, N
    Zoghbi, SS
    Seibyl, JP
    Charney, DS
    Innis, RB
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (07) : 1108 - 1114
  • [5] RECEPTOR ACTIVITY AND TURNOVER OF DOPAMINE AND NORADRENALINE AFTER NEUROLEPTICS
    ANDEN, NE
    BUTCHER, SG
    CORRODI, H
    FUXE, K
    UNGERSTEDT, U
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1970, 11 (03) : 303 - +
  • [6] WORKSHOP ON SCHIZOPHRENIA, PET, AND DOPAMINE D2 RECEPTORS IN THE HUMAN NEOSTRIATUM
    ANDREASEN, NC
    CARSON, R
    DIKSIC, M
    EVANS, A
    FARDE, L
    GJEDDE, A
    HAKIM, A
    LAL, S
    NAIR, N
    SEDVALL, G
    TUNE, L
    WONG, D
    [J]. SCHIZOPHRENIA BULLETIN, 1988, 14 (03) : 471 - 484
  • [7] Defining the phenotype of schizophrenia: Cognitive dysmetria and its neural mechanisms
    Andreasen, NC
    Nopoulos, P
    O'Leary, DS
    Miller, DD
    Wassink, T
    Flaum, L
    [J]. BIOLOGICAL PSYCHIATRY, 1999, 46 (07) : 908 - 920
  • [8] AMPHETAMINE PSYCHOSIS - BEHAVIORAL AND BIOCHEMICAL ASPECTS
    ANGRIST, B
    SATHANANTHAN, G
    WILK, S
    GERSHON, S
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 1974, 11 : 13 - 23
  • [9] DIFFERENTIAL-EFFECTS OF AMPHETAMINE AND NEUROLEPTICS ON NEGATIVE VS POSITIVE SYMPTOMS IN SCHIZOPHRENIA
    ANGRIST, B
    ROTROSEN, J
    GERSHON, S
    [J]. PSYCHOPHARMACOLOGY, 1980, 72 (01) : 17 - 19
  • [10] CLINICAL STUDIES WITH DOPAMINE-RECEPTOR STIMULANTS
    ANGRIST, B
    THOMPSON, H
    SHOPSIN, B
    GERSHON, S
    [J]. PSYCHOPHARMACOLOGIA, 1975, 44 (03): : 273 - 280